Stemline Therapeutics to Present at Upcoming Investor Conferences
Sep 20, 2017 11:00 am UTC| Business
NEW YORK, Sept. 20, 2017 -- Stemline Therapeutics, Inc. (Nasdaq:STML), a clinical-stage biopharmaceutical company developing novel therapeutics for difficult to treat cancers, announced that Ivan Bergstein, M.D.,...
New York Media Festival Returns to Manhattan with 15+ Events and 200+ Speakers, September 26-27
Sep 20, 2017 11:00 am UTC| Business
NEW YORK, Sept. 20, 2017 -- New York Media Festival, an innovative two-day event for the digital, games, music, television and video industries, will take place Tuesday, September 26, through Wednesday, September 27,...
Seasoned Software Investors Establish Elsewhere Partners to Focus on “Outliers”
Sep 20, 2017 11:00 am UTC| Business
AUSTIN, Texas, Sept. 20, 2017 -- Veteran software investors Chris Pacitti, John Thornton and Sam Kentor today launched Elsewhere Partners, a growth-stage venture capital firm. Elsewhere Partners invests exclusively in...
Knomatic and I2oT Solutions Announce One Year Anniversary of Technology Partnership
Sep 20, 2017 11:00 am UTC| Business
HOUSTON, Sept. 20, 2017 -- Knomatic, the leader in enterprise mobility, business workflow and process solutions, today announced that they have successfully collaborated with technology partner I²oT Solutions for the...
AGTC to Present at Upcoming Conferences
Sep 20, 2017 11:00 am UTC| Business
GAINESVILLE, Fla. and CAMBRIDGE, Mass., Sept. 20, 2017 -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene...
Sep 20, 2017 11:00 am UTC| Business
Dublin, Ohio, Sept. 20, 2017 -- Safeware, a leading provider of product protection and extended warranty solutions, has again been recognized on the Best Places to Work in Insurance list by Business Insurance and Best...
Sep 20, 2017 11:00 am UTC| Business
– The Primary Objective of Progression-Free Survival Favored Selinexor over Placebo; Hazard Ratio of 0.60 (RECIST v1.1), Representing a 40% Reduction in Risk of Progression or Death – – Phase 3 Portion of Study...